Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHCPR funding cut in half in House bill; ATP elimination also approved.

This article was originally published in The Gray Sheet

Executive Summary

COMMERCE'S ADVANCED TECHNOLOGY PROGRAM COULD GET PRESIDENTIAL REPRIEVE if President Clinton follows a recommenda-tion to veto the Department of Commerce funding bill (HR 2076) passed by the House in a 272-151 vote on July 26. The bill calls for eliminating the ATP program. In a July 18 letter to House Appropriations Chair Robert Livingston (R-La.), Office of Management and Budget Director Alice Rivlin said the Administration finds the bill "seriously objectionable" and that she, Commerce Secretary Ron Brown and Attorney General Janet Reno would recommend that Clinton veto the measure. The Senate has yet to take up consideration of the bill.
Advertisement

Related Content

FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
Advertisement
UsernamePublicRestriction

Register

MT004467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel